Expand all sections

Nedosiran

Extended indication

Primary Hyperoxaluria
Therapeutic value

No estimate possible yet
Registration phase

Clinical trials

Product

Active substance

Nedosiran
Domain

Metabolism and Endocrinology
Reason of inclusion

New medicine (specialité)
Main indication

Metabolic diseases
Extended indication

Primary Hyperoxaluria
Manufacturer

Novo Nordisk
Portfolio holder

Novo Nordisk
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

2024
Expected Registration

2025
Orphan drug

Yes
Registration phase

Clinical trials
Additional remarks 
NCT05993416

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.